Kexing Biopharm Co., Ltd. (SHA:688136)
China
· Delayed Price · Currency is CNY 25.89
-2.75 (-9.60%)
Apr 29, 2026, 3:00 PM CST
Kexing Biopharm Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 1,534 | 1,403 | 1,256 | 1,300 | 1,285 | Upgrade
|
| Other Revenue | - | 3.52 | 3.19 | 15.84 | 0.45 | Upgrade
|
| Revenue | 1,534 | 1,407 | 1,259 | 1,316 | 1,285 | Upgrade
|
| Revenue Growth (YoY) | 9.03% | 11.75% | -4.32% | 2.39% | 5.32% | Upgrade
|
| Cost of Revenue | 561.97 | 444.2 | 370.31 | 324.66 | 265.3 | Upgrade
|
| Gross Profit | 972.05 | 962.73 | 888.72 | 991.21 | 1,020 | Upgrade
|
| Selling, General & Admin | 668.04 | 682.73 | 776.11 | 913.6 | 846.08 | Upgrade
|
| Research & Development | 199.55 | 168.05 | 344.8 | 193.3 | 122.95 | Upgrade
|
| Other Operating Expenses | 6.86 | 12.03 | 11.46 | 9.69 | 9.78 | Upgrade
|
| Operating Expenses | 874.45 | 864.21 | 1,129 | 1,117 | 977.66 | Upgrade
|
| Operating Income | 97.61 | 98.52 | -240.71 | -125.34 | 42.21 | Upgrade
|
| Interest Expense | - | -44.85 | -40.72 | -28.7 | -8.03 | Upgrade
|
| Interest & Investment Income | 29.82 | 12.95 | 13.17 | 9.49 | 18.25 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.74 | 3.29 | 6.95 | -1.53 | Upgrade
|
| Other Non Operating Income (Expenses) | -39.63 | -0.58 | -0.76 | -1.78 | -3.88 | Upgrade
|
| EBT Excluding Unusual Items | 87.8 | 66.78 | -265.72 | -139.39 | 47.03 | Upgrade
|
| Gain (Loss) on Sale of Investments | 79.29 | -29.19 | 0.24 | -5.35 | 47.46 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.95 | 0.08 | 0.28 | 1.05 | -2.74 | Upgrade
|
| Asset Writedown | -2.34 | -0.17 | -1.6 | - | - | Upgrade
|
| Other Unusual Items | - | 19.41 | 6.73 | 4.63 | 3.88 | Upgrade
|
| Pretax Income | 165.7 | 56.9 | -260.07 | -139.06 | 95.63 | Upgrade
|
| Income Tax Expense | 12.96 | 29.85 | -64.58 | -46.24 | -0.84 | Upgrade
|
| Earnings From Continuing Operations | 152.74 | 27.05 | -195.49 | -92.82 | 96.46 | Upgrade
|
| Minority Interest in Earnings | 2.82 | 4.43 | 5.2 | 2.53 | - | Upgrade
|
| Net Income | 155.57 | 31.48 | -190.29 | -90.3 | 96.46 | Upgrade
|
| Net Income to Common | 155.57 | 31.48 | -190.29 | -90.3 | 96.46 | Upgrade
|
| Net Income Growth | 394.17% | - | - | - | -30.67% | Upgrade
|
| Shares Outstanding (Basic) | 197 | 197 | 198 | 201 | 197 | Upgrade
|
| Shares Outstanding (Diluted) | 197 | 197 | 198 | 201 | 197 | Upgrade
|
| Shares Change (YoY) | 0.08% | -0.74% | -1.21% | 1.93% | 31.59% | Upgrade
|
| EPS (Basic) | 0.79 | 0.16 | -0.96 | -0.45 | 0.49 | Upgrade
|
| EPS (Diluted) | 0.79 | 0.16 | -0.96 | -0.45 | 0.49 | Upgrade
|
| EPS Growth | 393.75% | - | - | - | -47.31% | Upgrade
|
| Free Cash Flow | 2.4 | 12.68 | -278.34 | -485.06 | -277.97 | Upgrade
|
| Free Cash Flow Per Share | 0.01 | 0.06 | -1.40 | -2.42 | -1.41 | Upgrade
|
| Dividend Per Share | - | 0.080 | - | - | 0.100 | Upgrade
|
| Dividend Growth | - | - | - | - | 25.00% | Upgrade
|
| Gross Margin | 63.37% | 68.43% | 70.59% | 75.33% | 79.36% | Upgrade
|
| Operating Margin | 6.36% | 7.00% | -19.12% | -9.53% | 3.28% | Upgrade
|
| Profit Margin | 10.14% | 2.24% | -15.11% | -6.86% | 7.51% | Upgrade
|
| Free Cash Flow Margin | 0.16% | 0.90% | -22.11% | -36.86% | -21.63% | Upgrade
|
| EBITDA | 195.58 | 184.6 | -167.64 | -70.32 | 77.41 | Upgrade
|
| EBITDA Margin | 12.75% | 13.12% | -13.31% | -5.34% | 6.02% | Upgrade
|
| D&A For EBITDA | 97.97 | 86.08 | 73.07 | 55.03 | 35.2 | Upgrade
|
| EBIT | 97.61 | 98.52 | -240.71 | -125.34 | 42.21 | Upgrade
|
| EBIT Margin | 6.36% | 7.00% | -19.12% | -9.53% | 3.28% | Upgrade
|
| Effective Tax Rate | 7.82% | 52.46% | - | - | - | Upgrade
|
| Revenue as Reported | - | 1,407 | 1,259 | 1,316 | 1,285 | Upgrade
|
| Advertising Expenses | - | - | - | - | 5.68 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.